Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

First Manhattan Wants to Replace Vivus CEO Wilson

By Pharmaceutical Processing | July 2, 2013

Vivus Inc.’s biggest shareholder said Tuesday that it plans to replace the company’s CEO if it is successful in gaining control of the obesity drug maker in an ongoing proxy fight.

First Manhattan Co., which holds about a 10-percent stake in Vivus, said it will name Anthony Zook as CEO if it wins control of the board. Zook was president of MedImmune Inc. before MedImmune was acquired by AstraZeneca, and he was head of global commercial operations for AstraZeneca PLC until February.

Leland Wilson, 69, has been CEO and a director of Vivus since 1991. The Mountain View, Calif., company declined to comment on First Manhattan’s proposal.

In March First Manhattan moved to replace Vivus’ entire board of directors by nominating six candidates. It said the launch of Vivus’ weight loss drug Qsymia has been unsuccessful and that the company should change its U.S. business strategy and get Qsymia approved in Europe. The firm, which owns a 9.9-percent stake in Vivus, added that the company needs new leadership.

Vivus has urged shareholders to reject First Manhattan’s nominees and said its board has the experience necessary to make Qsymia a success. The company’s annual shareholder meeting is scheduled for July 15.

The Food and Drug Administration approved Qsymia in July, and Vivus started selling it in September. So far sales have not lived up to Wall Street’s lofty expectations. Insurance coverage for Qsymia remains limited and out-of-pocket costs for patients are high. At first Qsymia was only available through mail order, which also limited sales. On Monday Vivus said the drug is now available at about 8,000 Walgreen Co. and Costco Wholesale Corp. pharmacies.

Vivus shares rose 27 cents, or 2.2 percent, to $12.68 in morning trading.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE